Not yet taking people in ChinaNo phase

A new PET scan tracer targeting 5T4 for lung and breast cancer

Tests the 68Ga-MY scan against 18F-FDG in adults with solid tumors.

Key facts

Who runs it: Peking University Cancer Hospital & Institute
Where: Beijing, ChinaSee the site
Trial code: NCT07589101
Registry title: 5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Status: Not yet recruiting
People taking part: 20 people, planned
Started: 1 Jun 2026
Expected to end: 30 Dec 2027
Type of study: Interventional
Treatments tested: 18F-FDG
68Ga-MY
Record updated: 15 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 70 with solid tumors. They will have PET/CT scans with a new tracer, 68Ga-MY, which will be compared with 18F-FDG.

Age: 18 to 70 years
Sex: All sexes can join.
Disease stage: Solid tumors with measurable lesions on imaging. Expected survival of at least 12 weeks.

Main reasons for not taking part

Severe liver or kidney problems
Planning pregnancy, pregnant, or breastfeeding
Cannot lie on the back for 30 minutes
Claustrophobia or other psychiatric disorders
Other conditions the investigator considers unsuitable for the trial

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

Patients with solid tumors
Presence of measurable lesions on imaging examinations
Expected survival ≥12 weeks

Who cannot take part

Diagnosis of claustrophobia or other psychiatric disorders
Other conditions deemed by the investigator as inappropriate for participation in the trial
Severe hepatic or renal dysfunction
Women who are planning pregnancy, pregnant, or breastfeeding
Unable to remain in supine position for 30 minutes
Refusal to participate in this clinical study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 70 years old?

Where in China

Beijing Cancer HospitalBeijing, ChinaContact: Hua ZhuNo longer taking part

About the trial

What the trial wants to find out

This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors.

Read full original descriptionShow less

The 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread.

In this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET/CT imaging using 68Ga-MY. The imaging results will be compared with 18F-FDG. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-MY PET/CT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.

The group in the trial

68Ga-MY PET ImagingTreatment being tested
All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-MY PET/CT scans.After the participant rests quietly for 40 minutes or 1 hour, whole-body imaging of the head and torso will be performed using a United Imaging uEXPLORER Whole-Body PET/CT scanner at 1 h, 2 h, and 3 h post-injection. The scan range will cover from the vertex to the upper third of the thighs. Participants who required a dynamic scan underwent a 40-min serial scan after injection of 68Ga-MY. PET/CT static imaging was performed at 2 h and 3 h after injection.
Treatment: 18F-FDG and 68Ga-MY